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Nuclear factor of activated T-cells (NFAT) and NF-kB pathway associated processes are involved in the pathogenesis of various
inflammatory disorders, for example, periodontal disease. The activation of these pathways is controlled by the regulator of
calcineurin 1 (RCAN1). The aim of this study was to elucidate the role of RCAN1 in periodontal disease. Healthy and inflamed
periodontal tissues were analyzed by immunohistochemistry and immunofluorescence using specific rabbit polyclonal anti-RCAN1
antibodies. For expression analysis human umbilical vein endothelial cells (HUVEC) were used. HUVEC were incubated for
2 h with Vascular Endothelial Growth Factor (VEGF) or with wild type and laboratory strains of Porphyromonas gingivalis (P.
gingivalis). Expression analysis of rcan1 and cox2 was done by real time PCR using specific primers for rcan1.4 and cox2. The
expression of rcan1 was found to be significantly suppressed in endothelial cells of chronically inflamed periodontal tissues
compared to healthy controls. Rcan1 and cox2were significantly induced by VEGF and wild type and laboratory P. gingivalis strains.
Interestingly, the magnitude of the rcan1 and cox2 induction was strain dependent. The results of this study indicate that RCAN1 is
suppressed in endothelial cells of chronically inflamed periodontal tissues. During an acute infection, however, rcan1 seems to be
upregulated in endothelial cells, indicating a modulating role in immune homeostasis of periodontal tissues.
1. Introduction
Periodontitis is a chronic inflammatory disease resulting in
the destruction of periodontal tissues and, if left untreated, in
tooth loss. It is well accepted that dysbiotic microbial com-
munities within the oral cavity are involved in the onset and
progression of periodontal diseases [1, 2].These communities
display synergistic virulence that can evade the host immune
response and trigger tissue-destructive inflammatory and
immune responses [3]. Many of these processes are under
control of the nuclear factor of activated T-cells (NFAT) [4, 5]
and the NF-kB pathway [6–10]. NFAT activation induces the
expression of various cytokines, including IL-2, IL-3, IL-4, IL-
5, IL-6, TNF-𝛼, and GM-CSF, whereas induction of NF-kB
results in an increased expression of inflammatory cytokines
like IL-1b, IL-6, TNF-𝛼, and IL-8 [9].
The regulator of calcineurin 1 (RCAN1) regulates NFAT
and NF-kB depending pathways. The human RCAN1 genes
are expressed as two isoforms, that is, RCAN1.1 and RCAN1.4
[11, 12]. While RCAN1.1 seems to be constitutively expressed
in most tissues, transcription of the RCAN1.4 variant is
induced de novo by several stimuli [13]. RCAN1 interacts
with cytosolic calcineurin to inhibit its phosphatase activity
and thus the dephosphorylation, nuclear translocation, and
activation of NFAT [5, 14, 15]. In addition to that RCAN1
led to enhanced stability of a family of NF-kB inhibitory
molecules thus suppressing the NF-kB pathway [9, 16].
RCAN1 is highly expressed in various tissues of the human
body, including heart, lung, kidney, brain, muscle, liver, and
testis [9]. Furthermore, it has been implicated in impor-
tant physiological and pathological processes, including cell
growth and immune regulation [13].
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The human rcan1 gene is located within the Down Syn-
drome critical region on chromosome 21 and is overexpressed
in individuals with trisomy 21 [17]. This overexpression
has been implicated to mediate some of the infectious
complications associated with this syndrome [9, 17]. In this
regard it is noteworthy that severe periodontitis is a common
manifestation among subjects with Down Syndrome, with
an estimated prevalence of 58–96% in those under 35 years
of age [18]. Moreover, the expression of rcan1 has also been
found to be upregulated in periodontal tissues following
mechanical stress and nonsurgical periodontal therapy [19,
20], indicating a role in homoeostasis of periodontal tissues.
Taken together these findings suggest that RCAN1 is
involved in the pathogenesis of periodontal diseases. There-
fore, the aim of the present study was to further assess the
potential role of RCAN1 in periodontal tissues by histological
and coincubation studies.
2. Materials and Methods
2.1. Tissue Samples Collection and Tissue Preparation.
Healthy (𝑛 = 6) and (𝑛 = 6) third molars with chronic
periodontitis that had to be extracted for orthodontic/
medical reasons were included in the study. The patients
agreed to have the tissue biopsies taken and examined for
research purposes. Procurement of human teeth tissues
at surgery was approved by the “Ethikkommission an der
Medizinischen Fakulta¨t der Heinrich-Heine-Universita¨t
Du¨sseldorf” (institutional review board of the Heinrich-
Heine-University Du¨sseldorf; IRB approval number 2980).
The patients agreed to have the extracted teeth examined for
research purposes. The molars and the adherent periodontal
ligament (PDL) were immersion-fixed in a fixative (4%
paraformaldehyde and 0.2% picric acid in 0.1M phosphate
buffer saline (PBS), pH 7.4) and demineralized for 21 days
in 4N formic acid. The samples were cryoprotected, frozen
embedded, and frozen-sectioned on a cryostat at 30 𝜇m
sections. To determine the health and inflammation state of
the teeth, sections were characterized by Haematoxylin and
Eosin (H&E) staining as previously described [21].
2.2. Immunohistochemistry
2.2.1. Avidin-Biotin-Peroxidase Staining. Sections of healthy
and inflamed molars were incubated for 48 h at 4∘C with
rabbit polyclonal anti-RCAN1. Then, sections were incu-
bated with biotin-conjugated goat anti-rabbit IgG (1 : 500)
and followed by avidin-biotin-peroxidase complex (Vector,
Burlingame, CA; 1 : 100).The signal was visualizedwith 0.05%
3,3󸀠-diaminobenzidine tetrahydrochloride (Sigma-Aldrich,
Taufkirchen, Germany). Incubations without the primary
antisera were carried out as immunohistochemical controls
[21].
2.2.2. Double-Immunofluorescence and Confocal Microscopy.
The free-floating sections were incubated with endothelial
cell marker mouse anti-CD31 (1 : 800) for 24 hrs at 4∘C.Then,
sections were incubated at 1 : 500 dilution with DyLight
488-conjugated goat anti-mouse IgG (Pierce Biotechnol.,
Rockford, IL) for 1 h at RT and with rabbit anti-RCAN1.4
(Santa Cruz, Heidelberg, Germany) for 24 hrs at 4∘C.
Thereafter, the sections were incubated with DyLight 549-
conjugated goat anti-rabbit IgG (Pierce; 1 : 500) for 1 h at
RT. The nuclei were stained for 15min with the DNA stain
DRAQ5 (Axxora, Lo¨rrach, Germany) at RT. The control
sections were incubated without mouse anti-CD31 and rabbit
anti-RCAN1.4 but with all reagents used in the immunohis-
tochemical incubations [21]. Three colour fluorescent images
were acquired on LSM 510 META confocal microscope (Carl
Zeiss, Jena, Germany). The confocal images through regions
of interest in each preparation at 0.1 𝜇m intervals throughout
the depth of the section were collected for each fluorochrome
at each z-step as described previously [21].
2.2.3. Densitometry of the Immunohistochemical Stainings.
The densitometric analysis was performed with a Zeiss
Axioskop-2 Plus microscope at 100x magnification coupled
with Image System Analysis, Axiovision Ver. 4.7 (Carl Zeiss,
Jena, Germany). G-intensities of RCAN1 in endothelium
of blood vessels of the healthy and inflamed periodontal
ligament were measured by grey values of immunostaining.
The background grey value wasmeasured from three selected
regions at a section-free area. The blood vessels grey values
were measured from three selected areas of the blood vessels.
Immunostaining intensity was presented as the mean of
measured blood vessels grey value minus mean of measured
background grey value [22].
2.3. Cell Culture. Human umbilical vein endothelial cells
(HUVEC) were purchased (Promocell, Heidelberg, Ger-
many) and grown in Endothelial Cell Growth Medium
(Promocell, Heidelberg, Germany) at 37∘C in a humidified
atmosphere of 95% air and 5% CO
2
in 75 cm2 flask until
70–90% confluence. The cells were harvested and seeded in
tissue culture 6-well plates (Sarstedt, Germany) with counts
of 60.000 cells/plate and used for experiments when having
reached 80% confluence. Cells were used for experiments
between passages 3 and 6. Cell viability was determined by
Trypan Blue exclusion test.
2.4. Bacterial Culture. Wild type Porphyromonas gingivalis
(P. gingivalis) were isolated from patients with chronic peri-
odontitis. Type strain P. gingivalis DSM 20709 was obtained
from the German Collection of Microorganisms and Cell
Cultures Inc. (DSMZ Braunschweig, Germany). All bacterial
strains were grown in liquid media containing 10% FCS,
3% TSB, 0.5% yeast, 0.05% L-cystein, 0.0005% hemin, and
0.001% vitamin K1 (all fromMerck, Germany), in an anaero-
bic chamber (Meintrup, Germany) at an atmosphere of 80%
N
2
, 10% H
2
, and 10% CO
2
. All stocks were grown to OD 0.5,
centrifuged, and resuspended in an equal volume of Endothe-
lial Cell GrowthMedium (Promocell, Heidelberg, Germany).
2.5. RCAN1 and COX2 Expression Assays. HUVEC in 6-
well plates grown to 80% confluence were incubated with
1mL bacterial suspension OD 0.5 or with 25 ng/mL Vascular
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Figure 1: Localization of RCAN1 in healthy and chronically inflamed periodontal ligament (PDL). d = dentin, pd = predentin, o =
odontoblasts, dp = dental pulp, rd = reactive dentin, PDL = periodontal ligament, and c = cementum. Asterisks indicate blood vessels (b) or
negative erythrocytes indicating blocked endogenous peroxidase in blood vessels (d). Bars: (a, c, e, g) 1mm; (b, d, f, h) 50𝜇m.
Endothelial Growth Factor (VEGF, Invitrogen Inc., Carlsbad,
USA) or medium only for control. All plates were incubated
for 2 h at 37∘C in a humidified atmosphere of 95% air and
5%CO
2
. Following incubation cells were washedwithHepes-
BSS, detached with Detach Kit (Promocell, Heidelberg, Ger-
many) and total RNA was isolated with Qiagen Qiashredder
and Qiagen RNeasy Mini Kit according to manufacturer’s
instructions (Qiagen, Germany). Quantity and quality check
of RNA was performed with Agilent Bioanalyzer. All experi-
ments were run in triplicate.
2.6. Real Time PCR. Complementary DNA was synthesized
using iScript cDNA Synthesis Kit (Bio-Rad, Germany).
Quantitative real time PCR was performed with 2.5 ng/𝜇L
cDNA for gapdh and 10 ng/𝜇L cDNA for rcan1 in a Bio-
Rad CFX-96 Real Time System using SsoFast Eva Green
Supermix (Bio-Rad, Germany). The qRT-PCR conditions
were 95∘C for 3min followed by 40 cycles of 95∘C for
10 s, 55∘C for 5 s, 60∘C for 10 s, and 77∘C for 1 s. To verify
that a specific product was amplified, a melting curve was
generated at the end of PCR. Gene specific primers used
were GAPDH f114 (5󸀠-GAGTCAACGGATTTGGTCGT-
3󸀠), GAPDH r260 (5󸀠-GACAAGCTTCCCGTTCTCAG-
3󸀠), and RCAN1 3r99 (5󸀠-GCTCTTAAAATACTGAAA-
GGTG-3󸀠) according to Yao and Duh [23], and RCAN
3F (5󸀠-TGACTGCGTGGGTCTGTAGCGC-3󸀠), COX2 exF1
(5󸀠-GCCTGGTCTGATGATGTATG-3󸀠), and exR (5󸀠-GGG-
TAATTCCATGTTCCAGC-3󸀠) designed for the present
study and specific for RCAN1.4 and COX2, respectively. PCR
products were verified by sequencing. Gene expression level
relative to gapdh and control was calculated asΔΔCqwith the
Bio-Rad CFX Manager 2.0 software (Bio-Rad, Germany).
2.7. Statistical Analysis. The statistical comparisons of the
densitometric measurements between healthy and inflamed
tissues were performed using Kruskal-Wallis test followed by
two-tailed Student’s 𝑡-test for paired samples. Differences in
the expression pattern betweenHUVEC control andHUVEC
test groups and between rcan1 and cox2 were analyzed by
two-tailed Student’s 𝑡-test for unpaired samples (SPSS, v.18,
Munich, Germany).The significance level was set at 𝑝 < 0.05.
3. Results
3.1. Localization of RCAN1 in Healthy and Chronically
Inflamed Periodontal Ligament (PDL). RCAN1 was detected
in blood vessels of the healthy PDL (Figure 1(a)). In higher
magnification of the overview picture, blood vessels (aster-
isks) were stained by RCAN1 (Figure 1(b)). After incuba-
tion without the primary antibodies, secondary antibodies
revealed no staining (Figure 1(c)). In higher magnification of
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Figure 2: Confocal microscopy and immunofluorescence of RCAN1 in PDL. Cell nuclei of the PDL cells were identified by DRAQ5 (a; blue).
The colocalization of CD31 (b: green; a marker for endothelial cells) and RCAN1 (c; red) in blood vessel walls of healthy PDL indicates that
RCAN1 is localized in blood vessel endothelia. ∗ = lumen of blood vessel (d; merge; yellow); white bar = 20 𝜇m.
c, negative erythrocytes (asterisks) indicated blocked endoge-
nous peroxidase in blood vessels of the PDL (Figure 1(d)).
In inflamed PDL, staining intensity for RCAN1 was lower
in blood vessels (asterisks) when compared with healthy PDL
(Figures 1(e) and 1(f)). Numerous inflammatory cells were
found in the PDL (Figure 1(f)). Incubation without the pri-
mary antibodies but with secondary antibodies only revealed
no staining in the inflamed control sections (Figures 1(g)
and 1(h)). In inflamed PDL, negative erythrocytes (asterisks)
indicated blocked endogenous peroxidase in blood vessels
(Figure 1(h)).
Densitometric analysis confirmed the significantly lower
staining intensity for RCAN1 in endothelial cells of the
inflamed (863.23 ± 49.60 densitometric unit) compared
to endothelial cells of the healthy PDL (1422.42 ± 90.65
densitometric unit) (Figure 3).
Confocal microscopy revealed expression of RCAN1 in
endothelial cells of PDL by colocalization of CD31 and
RCAN1. No colocalization with DRAQ5 and RCAN1 could
be detected, indicating that RCAN1 is typically not detectable
in the nuclei of PDL cells (Figures 2(a)–2(d)).
3.2. Expression of Rcan1 and Cox2 in Endothelial (HUVEC)
Cells. The incubation with VEGF for 2 h resulted in a
significantly (𝑝 < 0.05) 3.56 ± 0.33-fold increased expression
of rcan1 compared to the untreated control (see Figure 4).
In addition, wild type P. gingivalis significantly (𝑝 < 0.05)
increased the expression of rcan1 2.02 ± 0.16 to 3.64 ±
0.35-fold compared to untreated controls. Incubation with
the laboratory strain DSM 20709 induced a 5.9 ± 1.56-fold
increase in expression compared to untreated controls. The
increase was found to be significantly (𝑝 < 0.05) increased
compared to expression of rcan1 induced by wild type strains
of P. gingivalis as well as to the untreated control.
VEGF induced a significant 2.5 ± 0.1-fold increased (𝑝 <
0.05) expression of cox2 compared to the untreated control
(see Figure 5). The VEGF induced expression of cox2 was
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Figure 3: Densitometric analysis of RCAN1 in endothelial cells.
Staining intensities (densitometric units) for RCAN1 in healthy and
inflamed endothelial cells. Data are mean ± SD.
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Figure 4: Expression of rcan1 in endothelial (HUVEC) cells. Expres-
sion of rcan1 following 2 h incubation with medium (negative con-
trol), VEGF (positive control), and P. gingivalis strains DSM 20709,
WT 149, WT 880, WT 972, and WT 1019. Error bars indicate ±SD.
found to be significantly lower than the VEGF induced
expression of rcan1.
Wild type P. gingivalis significantly (𝑝 < 0.05) increased
the expression of cox2 in a range from 1.65 ± 0.15- to
4.32±0.18-fold compared to the untreated controls.The cox2
expression pattern induced by wild type P. gingivalis strains
was found to be similar and not statistically different from
the rcan1 expression.
Incubation with laboratory strain DSM 20709 resulted in
a 5.01 ± 1.05-fold increased expression of cox2 compared to
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Figure 5: Expression of cox2 in endothelial (HUVEC) cells. Expres-
sion of cox2 following 2 h incubation with medium (negative con-
trol), VEGF (positive control), and P. gingivalis strains DSM 20709,
WT 149, WT 880, WT 972, and WT 1019. Error bars indicate ±SD.
untreated controls.This increase was found to be significantly
(𝑝 < 0.05) increased compared to the cox2 induced
expression by wild type strains of P. gingivalis as well as to
the untreated control. Compared to the rcan1 expression,
however, theP. gingivalisDSM20709 induced cox2 expression
was found to be significantly lower.
4. Discussion
To our knowledge, this is the first reported histological
evidence of RCAN1 expression in endothelial cells of peri-
odontal tissues. Rcan1 is a VEGF target gene in endothelial
cells that regulates NFAT [5, 14, 15] and NF-kB dependent
pathways [9, 16] as well as other inflammatory mediators like
COX2, PGE
2
, and thromboxane [10, 15]. These are signaling
pathways and molecules that regulate the inflammatory
response in periodontal tissues.
RCAN1 has been found as both an inhibitor [24–26]
and an activator [27–29] of inflammation. The apparently
paradoxical actions of RCAN1 can be attributed to RCAN1’s
unique function in a negative feedback loop that regulates
its own expression [30] as well as the activity of calcineurin
[5, 10, 15]. Low or moderate levels of RCAN1 upregulate
and high levels of RCAN1 downregulate calcineurin signaling
suggesting that RCAN1 oscillates between stimulatory and
inhibitory forms depending on its concentration [14, 29,
31]. The functional role of RCAN1 may change in a dose-
dependent fashion but in the opposite direction to the
aforementioned studies. It has been reported that RCAN1 had
an inhibitory effect at low levels but an activating effect at
high levels [32]. The biological activity of rcan1 appears to be
highly cell and context dependent [5].The functional RCAN1
characteristics may be responsible for the seemingly conflict-
ing results of the present and previous studies on the role of
RCAN1 in periodontal tissues [20]. In the present study, the
staining densities were found to bemuch lower in chronically
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inflamed compared to healthy periodontal tissues.However, a
previous in vivo study has shown that the expression of rcan1
is higher in treated compared to healthy periodontal tissues
[20]. Based on these results one may speculate that rcan1 is
downregulated during chronic infection thus fostering the
immune response and upregulated during tissue regeneration
to limit the inflammatory response thatmay interferewith the
tissue repair. Although this interpretation is vaguely defined
and needs to be substantiated by additional studies, the data
of the above-mentioned studies indicate that the expression
of RCAN1 is at least differentially regulated in healthy as well
as in untreated and periodontally affected sites, respectively.
Rcan1 expression is mediated through numerous stimuli
including calcium-elevating agents and cell receptor agonists
like VEGF and thrombin [33]. Moreover, expression of rcan1
can be induced byGram-positive andGram-negative bacteria
[34]. The data of the present study show that the Gram-
negative putative periodontal pathogen P. gingivalis increases
the expression of rcan1 as much as VEGF, which is one of
the main regulators of rcan1. This and other results indicate
that TLR4 receptors may be involved in the regulation of
rcan1 [34]. Furthermore, the observed phenomenon might
display a short-termmechanism that limits the early immune
response towards P. gingivalis, thus avoiding any collateral
damage due to an overreacting inflammation.
Upon stimulation with VEGF and different P. gingivalis
strains the expression of cox2 followed almost the same
pattern compared to that of rcan1, indicating a common
mechanism that controls the expression of both genes. This
finding is supported by other studies demonstrating that cox2
and rcan1.4 are both upregulated by calcineurin-dependent
calcium signals [35, 36]. Mobilization of intracellular calcium
has been described to strongly augment the promoter activity
and mRNA and protein expression of rcan1.4 and cox2
[35]. For both genes, the calcium signal component has
been further found to be dependent on calcineurin and is
replicated by exogenous expression of a constitutively active
NFAT, strongly suggesting that the calcium-induced gene
activation is mediated by NFAT [35, 37].
It is presently thought that RCAN1 regulation of cal-
cineurin activity can be exploited to treat various inflamma-
tory diseases. With regard to periodontal inflammation it is
noteworthy that tacrolimus, a synthetic calcineurin inhibitor
like RCAN1, has been found to exert protective effects on
periodontal disease progression [38, 39] indicating that “fine
tuning” of the NFAT-RCAN1 negative feedback loops may
modulate inflammatory process in periodontitis.
In conclusion, the data of the present study provide the
first further evidence that RCAN1 may be involved in modu-
lating inflammation in a dependence of inflammation stages
manner and homeostasis in periodontal ligament. However,
additional studies in an animal model of periodontitis, for
example, RCAN1 knockout mice, are needed to substantiate
the importance of RCAN1 in periodontal disease.
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